Fort Huachuca-Sierra Vista, AZ, Sierra Vista Muni-Libby AAF, GPS RWY 8, Orig-B, CANCELLED
Fort Huachuca-Sierra Vista, AZ, Sierra Vista Muni-Libby AAF, GPS RWY 26, Orig-A, CANCELLED
Yuma, AZ, Yuma MCAS-Yuma Intl, VOR RWY 17, Amdt 5A, CANCELLED
Yuma, AZ, Yuma MCAS-Yuma Intl, VOR/DME OR TACAN–1 RWY 17, Amdt 1B, CANCELLED
Yuma, AZ, Yuma MCAS-Yuma Intl, VOR/DME RNAV RWY 21R, Amdt 4A, CANCELLED
Yuma, AZ, Yuma MCAS-Yuma Intl, ILS RWY 21R, Amdt 5A, CANCELLED
Yuma, AZ, Yuma MCAS-Yuma Intl, GPS RWY 17, Orig-B, CANCELLED
Yuma, AZ, Yuma MCAS-Yuma Intl, GPS RWY 21R, Orig-A, CANCELLED
Yuma, AZ, Yuma MCAS-Yuma Intl, Takeoff Minimums and Textual DP, Amdt 2, CANCELLED
Los Angeles, CA, Los Angeles Intl, Takeoff Minimums and Textual DP, Amdt 11
Visalia, CA, Visalia Muni, NDB RWY 30, Amdt 3B, CANCELLED
Aspen, CO, Aspen-Pitkin County/Sardy Field, LOC/DME–E, Orig
Washington, DC, Washington Dulles Intl, ILS OR LOC RWY 1R, ILS RWY 1R (CAT II), ILS RWY 1R (CAT III), Amdt 23
Washington, DC, Washington Dulles Intl, ILS OR LOC RWY 19L, Amdt 12
Washington, DC, Washington Dulles Intl, CONVERGING ILS RWY 19L, Amdt 6
Caldwell, ID, Caldwell Industrial, NDB RWY 30, Amdt 1
Caldwell, ID, Caldwell Industrial, RNAV (GPS) RWY 12, Orig
Caldwell, ID, Caldwell Industrial, RNAV (GPS) RWY 30, Orig
Caldwell, ID, Caldwell Industrial, GPS RWY 12, Orig-A, CANCELLED
Caldwell, ID, Caldwell Industrial, GPS RWY 30, Orig-A, CANCELLED
Caldwell, ID, Caldwell Industrial, Takeoff Minimums and Textual DP, Amdt 5
Terre Haute, IN, Terre Haute International-Hulman Field, RNAV (GPS) RWY 14, Orig
Terre Haute, IN, Terre Haute International-Hulman Field, RNAV (GPS) RWY 32, Orig
Terre Haute, IN, Terre Haute International-Hulman Field, GPS RWY 32, Orig, CANCELLED
Terre Haute, IN, Terre Haute International-Hulman Field, VOR/DME RNAV RWY 32, Amdt 8, CANCELLED
Slidell, LA, Slidell, RNAV (GPS) RWY 36, Orig-A
Jefferson City, MO, Jefferson City Meml, LOC BC RWY 12, Amdt 6D, CANCELLED
Joplin, MO, Joplin Regional, RNAV (GPS) RWY 13, Orig
Joplin, MO, Joplin Regional, RNAV (GPS) RWY 18, Orig
Joplin, MO, Joplin Regional, RNAV (GPS) RWY 31, Orig
Joplin, MO, Joplin Regional, RNAV (GPS) RWY 36, Orig
Joplin, MO, Joplin Regional, ILS OR LOC/DME RWY 18, Amdt 2
Joplin, MO, Joplin Regional, ILS OR LOC/NDB RWY 13, Orig
Joplin, MO, Joplin Regional, ILS RWY 13, Amdt 23B, CANCELLED
Joplin, MO, Joplin Regional, LOC BC RWY 31, Amdt 21
Joplin, MO, Joplin Regional, GPS RWY 13, Orig, CANCELLED
Joplin, MO, Joplin Regional, GPS RWY 18, Orig, CANCELLED
Joplin, MO, Joplin Regional, GPS RWY 36, Orig-A, CANCELLED
Joplin, MO, Joplin Regional, NDB RWY 13, Amdt 25
Joplin, MO, Joplin Regional, Takeoff Minimums and Textual DP, Amdt 4
Billings, MT, Billings Logan Intl, RNAV (GPS) RWY 10L, Amdt 1
Billings, MT, Billings Logan Intl, RNAV (GPS) RWY 28R, Amdt 1
Berlin, NH, Berlin Muni, NDB RWY 18, Orig-C, CANCELLED
Blairstown, NJ, Blairstown, VOR RWY 25, Amdt 2
Blairstown, NJ, Blairstown, RNAV (GPS) RWY 7, Orig
Blairstown, NJ, Blairstown, RNAV (GPS) RWY 25, Orig
Blairstown, NJ, Blairstown, GPS RWY 7, Orig, CANCELLED
Middletown, NY, Randall, RNAV (GPS) RWY 8, Orig
Middletown, NY, Randall, RNAV (GPS) RWY 26, Orig
Middletown, NY, Randall, GPS RWY 8, Orig, CANCELLED
Middletown, NY, Randall, GPS RWY 26, Orig, CANCELLED
Tulsa, OK, Richard Lloyd Jones Jr, RNAV (GPS) RWY 1L, Orig
Tulsa, OK, Richard Lloyd Jones Jr, ILS OR LOC RWY 1L, Amdt 1
Tulsa, OK, Richard Lloyd Jones Jr, GPS RWY 1L, Orig-A, CANCELLED
Eugene, OR, Mahlon Sweet Field, VOR/DME OR TACAN RWY 34L, Amdt 4D
Eugene, OR, Mahlon Sweet Field, VOR/DME OR TACAN RWY 16R, Amdt 4C
Eugene, OR, Mahlon Sweet Field, NDB RWY 16R, Amdt 29D
Eugene, OR, Mahlon Sweet Field, ILS OR LOC RWY 16R, ILS RWY 16R (CAT II), Amdt 34C
St. Marys, PA, St. Marys Muni, RNAV (GPS) RWY 10, Orig
St. Marys, PA, St. Marys Muni, VOR/DME RNAV RWY 10, Amdt 5B, CANCELLED
Rapid City, SD, Rapid City Regional, RNAV (GPS) RWY 14, Amdt 1
Millington, TN, Millington Muni, GPS RWY 4, Orig-A, CANCELLED
Millington, TN, Millington Muni, RNAV (GPS) RWY 4, Orig

The FAA published an Amendment in Docket No. 30447, Amdt No. 3124 to Part 97 of the Federal Aviation Regulations (Vol 70, FR No. 115, pages 34992–34993; dated June 16, 2005) under section 97.33 effective 7 JUL 2005, which is hereby rescinded:

Castroville, TX, Castroville Muni, RNAV (GPS) RWY 15, Orig
Raton, NM, Raton Municipal/Crews Field, NDB RWY 2, Amdt 5

[FR Doc. 05–12362 Filed 6–22–05; 8:45 am]
BILLING CODE 4910–13–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 522

Implantation or Injectable Dosage Form New Animal Drugs; Embutramide, Chloroquine, and Lidocaine Solution

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an original new animal drug application (NADA) filed by Phoenix Scientific, Inc. The NADA provides for veterinary prescription use of a solution containing embutramide, chloroquine phosphate, and lidocaine by intravenous injection for euthanasia of dogs.

DATES: This rule is effective June 23, 2005.

FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for Veterinary Medicine (HFV–110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–7543, e-mail: *melanie.berson@fda.gov*.

SUPPLEMENTARY INFORMATION: Phoenix Scientific, Inc., 3915 South 48th Street Ter., St. Joseph, MO 64503, filed NADA 141 245 that provides for veterinary prescription use of TRIBUTAME Euthanasia Solution (embutramide; chloroquine phosphate, U.S.P.; and lidocaine, USP) by intravenous injection for euthanasia of dogs. The NADA is approved as of May 20, 2005, and the regulations are amended in 21 CFR part 522 by adding § 522.810 to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for 3 years of marketing exclusivity beginning May 20, 2005.

FDA has determined under 21 CFR 25.33(d)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of ''rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ''particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subject in 21 CFR Part 522

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is amended as follows:

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 2. Section 522.810 is added to read as follows:

§ 522.810 Embutramide, chloroquine, and lidocaine solution.

(a) *Specifications*. Each milliliter (mL) of solution contains 135 milligrams (mg) embutramide; 45 mg chloroquine phosphate, U.S.P.; and 1.9 mg lidocaine, U.S.P.

(b) *Sponsor*. See No. 059130 in § 510.600(c) of this chapter.

(c) *Conditions of use in dogs*—(1) *Amount*. One mL per 5 pounds of body weight.

(2) *Indications for use*. For euthanasia.

(3) *Limitations*. Not for use in animals intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dated: June 10, 2005.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 05–12422 Filed 6–22–05; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 522 and 556

New Animal Drugs; Moxidectin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Fort Dodge Animal Health. The NADA provides for use of an injectable moxidectin solution for the treatment and control of various internal and external parasites of cattle.

DATES: This rule is effective June 23, 2005.

FOR FURTHER INFORMATION CONTACT: Joan C. Gotthardt, Center for Veterinary Medicine (HFV–130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–7571, e-mail: *jgotthar@cvm.fda.gov*.

SUPPLEMENTARY INFORMATION: Fort Dodge Animal Health, Division of Wyeth, 800 Fifth St. NW., Fort Dodge, IA 50501, filed NADA 141–220 that provides for use of CYDECTIN (moxidectin) Injectable Solution for Beef and Nonlactating Dairy Cattle for the treatment and control of various internal and external parasites. The NADA is approved as of May 20, 2005, and the regulations are amended in part 522 (21 CFR part 522) by adding § 522.1450 and in part 556 (21 CFR part 556) by revising § 556.426 to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for 3 years of marketing exclusivity beginning May 20, 2005.

The agency has carefully considered the potential environmental impact of this action and has concluded that the action will not have a significant impact on the human environment and that an environmental impact statement is not required. FDA's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

This rule does not meet the definition of ''rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ''particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects

21 CFR Part 522

Animal drugs.

21 CFR Part 556

Animal drugs, Foods.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under the authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 522 and 556 are amended as follows:

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 2. Section 522.1450 is added to read as follows:

§ 522.1450 Moxidectin solution.

(a) *Specifications*. Each milliliter of solution contains 10 milligrams (mg) moxidectin.

(b) *Sponsor*. See No. 000856 in § 510.600(c) of this chapter.

(c) *Related tolerances*. See § 556.426 of this chapter.

(d) *Conditions of use in beef and nonlactating dairy cattle.*—(1) *Amount*. 0.2 mg/kilogram body weight (0.2 mg/2.2 pound) as a single subcutaneous injection.

(2) *Indications for use*. For treatment and control of gastrointestinal roundworms: *Ostertagia ostertagi* (adults and inhibited fourth-stage larvae), *Haemonchus placei* (adults), *Trichostrongylus axei* (adults), *T. colubriformis* (fourth-stage larvae), *Cooperia oncophora* (adults), *C. punctata* (adults and fourth-stage larvae), *C. surnabada* (adults and fourth-stage larvae), *Oesophagostomum radiatum* (adults and fourth-stage larvae), *Trichuris* spp. (adults); lungworms: *Dictyocaulus viviparus* (adults and fourth-stage larvae); grubs: *Hypoderma bovis* and *H. lineatum*; mites: *Psoroptes ovis* (*P. communis* var. *bovis*); lice: *Linognathus vituli* and *Solenopotes capillatus*; for protection of cattle from reinfection with *D. viviparus* and *O. radiatum* for 42 days after treatment, with *H. placei* for 35 days after treatment, and with *O. ostertagi* and *T. axei* for 14 days after treatment.

(3) *Limitations*. Do not slaughter cattle within 21 days of treatment. Because a withholding time for milk has not been established, do not use in female dairy